Pancreatic Diabetes Mellitus and Heavy Drinking are Risk Factors for the Development of Liver Fibrosis in Alcoholic Chronic Pancreatitis

Gábor Zsóri1, Mátyás Czepán2, Dóra Illés2, Attila Pálvölgyi2, István Nagy1 and László Czakó1

Albert Szent-Györgyi Medical and Pharmaceutical Center, First Department of Medicine, Szeged 6720 Korányi Avenue 8-10, Hungary

Corresponding author: Gábor Zsóri, University of Szeged, Faculty of Medicine, Albert Szent-Györgyi Medical and Pharmaceutical Center, First Department of Medicine, Szeged 6720 Korányi Avenue 8-10, Hungary; Tel: +36-62-545-186; Fax: +36-62-545-185; E-mail: zsori.gabor861@gmail.com

Received date: June 09, 2017; Accepted date: July 11, 2017; Published date: July 15, 2017

Abstract

Objective: The coincidence of chronic pancreatitis and liver cirrhosis in alcoholic patients is comparatively rare. Our aim was to assess liver fibrosis in patients with alcoholic chronic pancreatitis (ACP) by measuring noninvasive fibrosis scores and liver stiffness.

Methods: Fifty-five patients with ACP were enrolled in the study. Eight healthy volunteers served as controls. Noninvasive fibrosis scoring systems, including the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 score (FIB-4), were determined and transient elastography (TE) was performed.

Results: Mild (F1 or F2) and severe (F3 or F4) fibrosis was revealed by TE in 15 and 6 patients (38.2%), respectively. However, the levels of the liver enzymes were elevated in only 12 patients. The APRI and FIB-4 scores jointly revealed fibrosis of the liver in two patient. ACP patients with liver fibrosis drank significantly more amount of alcohol and had diabetes more frequently than ACP patients without liver fibrosis.

Conclusion: Liver fibrosis was revealed by TE in one-fourth of the ACP patients. Liver enzymes are not reliable parameters with which to diagnose liver fibrosis. The quantity of consumed alcohol and the presence of DM are risk factors for the development of liver fibrosis in ACP.

Keywords: Chronic pancreatitis; Liver fibrosis; Diabetes mellitus; Transient elastography; Liver enzymes

Abbreviations: ACP: Alcoholic Chronic Pancreatitis; ALC: Alcoholic Liver Cirrhosis; APRI: Aspartate Aminotransferase to Platelet Ratio Index; CP: Chronic Pancreatitis; CT: Computed Tomography; DM: Diabetes Mellitus; ERCP: Endoscopic Retrograde Cholangiopancreatography; FIB-4: Fibrosis-4 Score; MRCP: Magnetic Resonance Cholangiopancreatography; TE: Transient Elastography; US: Abdominal Ultrasonography.

Introduction

Although chronic ethanol consumption is a common etiological factor, the coincidence of chronic pancreatitis (CP) and liver cirrhosis in alcoholic patients is relatively rare [1,2]. Different morphological and functional examinations have revealed the presence of alcoholic liver fibrosis (ALF) in only 10-20% of alcoholic CP (ACP) patients [3-6]. The rare coincidence of clinical and morphological alterations in ALF and ACP, and an inverse correlation between the indices of the pancreatic and liver functions evaluated by the fecal elastase-1 test and the indocyanine green test have been described [7]. These results support the hypothesis of the independent pathogenesis of ALF and ACP and suggest the presence of another etiological factor such as a genetic predisposition [8].

It may be assumed that the sociobehavioral factors of ACP and ALF also differ. ACP has been found to be more common in patients who smoke, have a long-term history of alcohol consumption, and prefer to drink spirits, and have a relatively low level of education [9], whereas ALF was reported to be more frequent in smokers [1]. The duration of chronic alcohol abuse proved to be shorter in ACP than in ALF, and cirrhosis was more characteristic among older subjects [3,10]. According to Gullo et al. the duration of alcohol consumption was significantly longer in ACP patients with ALF than in ACP patients without ALF [11].

Although liver biopsy is currently the gold standard for the diagnosis of liver cirrhosis, it has many drawbacks, such as the sampling error, the cost, and the risk of complications [12-14]. Noninvasive markers are increasingly used for the assessment of liver fibrosis, such as serum biomarkers and transient elastography (TE). TE was originally developed to measure the stage of liver fibrosis by assessing the stiffness of the liver in a noninvasive manner through the use of ultrasonography in cases of chronic hepatitis C infection [15-19]. TE has been demonstrated to be a suitable method to reveal the severity of liver fibrosis in CP and concomitant cholestasis through measurement of the liver stiffness [6]. It is also useful to predict outcome in portal hypertension, varical bleeding, hepatocellular carcinoma and postoperative patients [20-22].

The aim of the present study was to assess the liver fibrosis in patients with CP by measuring noninvasive fibrosis scores and liver stiffness by means of TE.

Patients and Methods

Patients with ACP were enrolled in the study and volunteers were recruited to serve as controls. CP was diagnosed on the basis of...
morphological diagnostic criteria [23,24]. Abdominal ultrasonography (US) and computed tomography (CT) were performed in all patients. Magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound was performed when CT was equivocal. Fecal elastase-1 test was performed to diagnose exocrine pancreatic function in some patients. Patients with cystic fibrosis and other etiologies of CP, cholestasis and viral, metabolic and autoimmune liver diseases were excluded from the study.

Noninvasive fibrosis scores including the aspartate aminotransferase to platelet ratio index (APRI) [25] and fibrosis-4 score (FIB-4) [26] were determined.

TE was performed with a Fibroscan 402 (Echosens, Paris, France) device. Measurements were made from one to three measuring points; the success rate was 78-100% with an average of 21 (10-42) valid shots per patient, expressed in kilopascals (kPa). The European Association for the Study of Liver (EASL) Clinical Practice Guideline was used to evaluate the measured values [27]. Fibrosis was staged by the Metavir scoring system [28-31] and TE results were compared with the noninvasive fibrosis scoring parameters.

All participants provided their written informed consent. The study protocol was in full accordance with the most recent revisions of the Helsinki Declaration and was approved by the ethics committee at the University of Szeged. SPSS 22.0 (Armonk, New York, USA) was used for the two samples t-test and chi-square test. P<0.05 was considered statistically significant.

Results
Fifty five consecutive patients (39 males and 18 females, mean age 61.85 ± 9.85 years, mean BMI 23.83 ± 4.4 kg/m²) with ACP and 8 healthy volunteers (4 males and 4 females, mean age 53 ± 10 years, mean BMI 22.1 ± 3 kg/m²) as controls were enrolled in the study. All the ACP patients previously had regularly consumed alcohol, but only 12 (21.8%) were still active drinkers at the enrolment. 77% of the patients were additionally smokers, and 35 (63.6%) were active smokers at the enrolment.

The clinical characteristics of ACP patients with and without liver fibrosis were compared (Table 2). ACP patients with liver fibrosis drank significantly more amount of alcohol and had diabetes more frequently than ACP patients without liver fibrosis.

| Cases | Controls |
|-------|----------|
| Successful transient elastography | 55 | 8 |
| Metavir stages | |
| F0 | 34 | 8 |
| F1 or F2 | 15 | 0 |
| F3 or F4 | 6 | 0 |
| Elevated levels of liver enzymes | |
| F0 | 6 | 0 |

Table 2: Clinical characteristics of alcholic chronic pancreatitis patients.

Table 1: Transient elastography, liver enzymes and noninvasive fibrosis scoring results on patients with alcoholic chronic pancreatitis.

| FIB-4 score | No. of cases (%) | ACP with liver fibrosis | ACP without liver fibrosis | p values |
|-------------|------------------|-------------------------|---------------------------|----------|
| APRI | | | | |
| ≤ 0.7 | 53 | 8 |
| 0.71-1.0 | 0 | 0 |
| <1.0 | 2 | 0 |
| F0 or F2 | 1 | 0 |
| F3 or F4 | 5 | 0 |

Table 1: transient elastography, liver enzymes and noninvasive fibrosis scoring results on patients with alcoholic chronic pancreatitis.
Discussion

Although the main etiological factor of ACP and ALF is common, the association of the two diseases is rather low. Previous studies with the following methods described the presence of liver fibrosis in 10-20% of patients with ACP: ERCP and secretin-beruclein test (12.5%) [3], liver biopsy (13.3%) [4], autopsy (20%) [5] and TE (10-15%) [6].

TE is a diagnostic modality that can assess the extent of liver fibrosis. The method has been evaluated extensively in patients with chronic hepatitis C infection [15-19]. It was recently demonstrated, that the degree of liver stiffness measured by TE in CP patients with concomitant cholestasis was correlated with the histologically indicated stage of liver fibrosis [6].

The aim of the current prospective study was to assess the occurrence of liver fibrosis in patients with CP by measuring noninvasive fibrosis scores and liver stiffness with TE. CP patients, diagnosed by imaging modalities, such as CT, MRCP, EUS were enrolled. CT has a good accuracy revealing the characteristic morphological alterations (calcification, pancreatic duct dilatation, pancreatic atrophy) in our patients with advanced CP.

The etiology of the pancreatitis was alcohol abuse in all patients. Among the noninvasive fibrosis scores, the levels of liver enzymes were elevated in 12 patients and the APRI and FIB-4 score were both normal except in six case. However, TE identified liver fibrosis in 21 (38.2%) of the ACP patients. These results suggest that the levels of the liver enzymes and the noninvasive fibrosis scores are not reliable parameters with which to reveal liver fibrosis in ACP. The effectiveness of the use of these noninvasive scores was earlier demonstrated to be lower than that of TE in diagnosing liver cirrhosis [6]. Furthermore, liver fibrosis in ACP patients was diagnosed by TE more frequently in our study than published earlier. This could be explained that patients in our study had long standing, advanced ACP with calcification, endocrine insufficiency and pancreatic surgery. We compared the characteristics of the ACP patients with or without TE-diagnosed liver fibrosis. The amount of alcohol consumption was higher and DM due to FCP (type III/c diabetes) was significantly more frequent in ACP patients with liver fibrosis than in those without liver fibrosis. These results may suggest that the toxic injury was more severe and prolonged and the severity of ACP was more advanced in the ACP patients with liver fibrosis group [32,33]. Moreover, DM may induce steatohepatitis, which may act synergistic ally with alcohol to result in the liver parenchyma alterations and the TE findings [34,35]. DM was more frequent in our ACP patients than in a previous study [6] and this may explain the higher rate of ALF in our study as compared to the previous results.

The two major causes of chronic liver disease in patients with ACP are alcohol abuse and/or compression of the biliary duct [1,3,9-11,36]. Cholestasis due to the fibrous pancreatic head was an exclusion criterion in our study, and therefore only the toxic etiology of the liver injury was assessed.

The drawbacks of our study include the low number of recruited patients and the fact that liver fibrosis indicated by TE was not always confirmed by histological examination. Liver biopsy is regarded as the gold standard for the assessment of the presence of liver fibrosis, but this technique is associated with a significant rate of complications [37].

The use of TE may be of particular interest in ACP patients because an abnormal finding is strongly suggestive of a fibrogenic process of the liver. The early detection of ALF may influence the prognosis of the disease.

The present study demonstrated the presence of liver fibrosis through the use of TE in around one-third of ACP patients. The levels of liver enzymes and noninvasive fibrosis scores are not reliable parameters with which to reveal liver fibrosis in ACP. The quantity of consumed alcohol and the presence of DM are risk factors for the development of liver fibrosis in ACP.

Conflict of Interest

We have no commercial associations that might be a conflict of interest in relation to the submitted manuscript.

References

1. Nakamura Y, Kobayashi Y, Ishikawa A, Maruyama K, Higuchi S (2004) Severe chronic pancreatitis and severe liver cirrhosis have different frequencies and are independent risk factors in male Japanese alcoholics. J Gastroenterol 39: 879-887.
2. Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, et al. (1991) Exocrine pancreatic function in chronic liver diseases. Am J Gastroenterol 86: 201-204.
3. Angelini G, Merigo F, Degani G, Camplani N, Bovo P, et al. (1985) Association of chronic alcoholic liver and pancreatic disease: a prospective study. Am J Gastroenterol 80: 998-1003.
4. Dani R, Nogueira CE, Ribeiro M, Nunes A (1983) Concomitance of hepatic lesions with chronic calcifying pancreatitis in the alcoholic. Study of 60 cases. Am J Gastroenterol 20: 103-107.
5. Renner JG, Savage WT, Stace NH, Pantoja JL, Schultheis WM, et al. (1984) Pancreatitis associated with alcoholic liver disease. A review of 1022 autopsy cases. Dig Dis Sci 29: 593-599.
6. Frossard JL, Gistro E, Rubbia-Brandt L, Hadengue A, Spahr I. (2013) The role of transient elastography in the detection of liver disease in patients with chronic pancreatitis. Liver Int 33: 1121-1127.
7. Aparasi L, Sabater L, Del-Olmo J, Sastre J, Serra MA, et al. (2008) Does an association exist between chronic pancreatitis and liver cirrhosis in alcoholic subjects? J Gastroenterol 14: 6171-6179.
8. Whitcomb DC (2003) Genetic predisposition to alcoholic chronic pancreatitis. Pancreas 27: 321-326.
9. Spicak J, Pulkertova A, Kralova-Lesna I, Suchanek P, Vitaskova M, et al. (2012) Alcoholic chronic pancreatitis and liver cirrhosis: coincidence and differences in lifestyle. Pancreatology 12: 311-316.
10. Ichihara S, Sato M, Koziuka S (1992) Prevalence of pancreatitis in liver diseases of various etiologies: an analysis of 107,754 adult autopsies in Japan. Digestion 51: 86-94.
11. Gullo L, Casadei R, Campione O, Grigioni W, Marrano D (1995) Alcoholic liver disease in alcoholic chronic pancreatitis: a prospective study. Ital J Gastroenterol 27: 69-72.
12. Myers RP, Fong A, Shaheen AA (2008) Utilization rates, complications and costs of percutaneous liver biopsy: A population-based study including 4275 biopsy. Liver Int 28: 705-712.
13. Regev A, Berho M, Jeffers LJ, Milikowsky C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.
14. Kan YY, Marquez AV, Ford JA, Peter Kwan WC, Erb SR, et al. (2015) Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol 29: 72-76.
15. Group TFMcs (1994) Intraobserver and interobserver variations in the liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 15-20.
16. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, et al. (2008) Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. J Gastroenterol 134: 960-74.

17. Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR, et al. (2010) A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 44: 214-219.

18. Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 1409-1414.

19. DelPoggio P, Colombo S (2009) Is transient elastography a useful tool for screening liver disease? J Gastroenterol 15: 1409-1414.

20. Grace Lai-Hung W (2013) Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep 1-8.

21. Bardou-Jacquet E, Legros L, Soro D, Latournerie M, Guillygomarch A, et al. (2013) Effect of alcohol consumption on liver stiffness measured by transient elastography. J Gastroenterol 19: 516-522.

22. Vergniol J, Foucher J, Terrebonne E, Bernard PH, Le Bail B, et al. (2011) Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 140: 1970-1979.

23. Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, et al. (2014) American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: Evidence-Based Report on Diagnostic Guidelines. Pancreas 43(8): 1143-1162.

24. Löhr JM, Dominguez-Munoz E, Rosen Dahl J, Besselink M, Mayerle J, et al. (2017) United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J 5: 153-199.

25. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, et al. (2011) Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53: 726-36.

26. Sterling RK, Lissen E, Cluneck N, Sola R, Correa MC, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 43: 1317-1325.

27. European Association for the Study of the Liver (2015) EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63: 237-264.

28. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408.

29. Laurent C, Xavier F, Alfredo A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847.

30. The French Metavir Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 15-20.

31. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP (2006) An appraisal of the histopathological assessment of liver fibrosis. Gut 55: 569-578.

32. Diego GC, Joel QJ, Jose AGG, Hector MG (2009) Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. J Gastroenterol 15: 280-288.

33. Gavin NL, Anthony ST (1992) Liver disease and diabetes mellitus. Clinical Diabetes 17.

34. Koecher EM, Plompen EP, Schouten JN, Hansen BE, Darwish MS, et al. (2016) Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam Study. Hepatology 63: 138-47.

35. Petta S, Maida M, Macaluso FS, Di Marco V, Cama M, et al. (2015) The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 62: 1101-1110.

36. Afroudakis A, Kaplowitz N (1981) Liver histopathology in chronic common bile duct stenosis due to chronic alcoholic pancreatitis. Hepatology 1: 65-72.

37. Maurizio S, Lydia G, Melchiore C, Anna I, Giuseppe M (2014) Non invasive tools for the diagnosis of liver cirrhosis. J Gastroenterol 20: 18131-18150.